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ABSTRACT
Splicing of human pre-mRNA is reciprocally coupled
to 30 end formation by terminal exon definition,
which occurs co-transcriptionally. It is required for
the final maturation of most human pre-mRNAs and
is therefore important to understand. We have used
several strategies to block splicing at specific
stages in vivo and studied their effect on 30 end for-
mation. We demonstrate that a terminal splice
acceptor site is essential to establish coupling
with the poly(A) signal in a chromosomally
integrated b-globin gene. This is in part to alleviate
the suppression of 30 end formation by U1 small
nuclear RNA, which is known to bind pre-mRNA at
the earliest stage of spliceosome assembly.
Interestingly, blocks to splicing that are subsequent
to terminal splice acceptor site function, but before
catalysis, have little observable effect on 30 end for-
mation. These data suggest that early stages of
spliceosome assembly are sufficient to functionally
couple splicing and 30 end formation, but that on-
going intron removal is less critical.
INTRODUCTION
Most human pre-mRNAs contain multiple introns that
are removed by splicing. The splicing process has two
catalytic steps with the ﬁrst releasing the 50 exon and the
second joining the two exons together with consequent
release of an intron lariat (1). It is performed by a set of
ﬁve small nuclear RNAs (snRNAs) in concert with 100 s
of protein factors. Intronic sequences, such as the 50 and 30
splice site, intervening branch-point and polypyrimidine
tract, play a vital role (2). The function of snRNAs in
splicing has been well characterized through decades of
study using both in vitro and in vivo systems. First, U1
snRNA (U1) contacts the 50 splice site after which U2
snRNA (U2) is recruited to the branch-point following
recognition of the 30 splice site and polypyrimidine tract
by U2AF35 and 65, respectively. U4, U5 and U6 snRNAs
then join, and two-step catalysis occurs after U1 and U4
are ejected from the spliceosome (2). Splicing of most
introns in higher eukaryotes is thought to occur by deﬁn-
ition of the comparatively shorter exons, across which 30
and 50 splice sites are recognized by U2 and U1, respect-
ively (3).
The majority of pre-mRNAs undergo cleavage and
polyadenylation at their 30 ends. This process requires a
poly(A) (pA) signal within the RNA, which is composed
of a hexameric sequence, usually AAUAAA, followed by a
U or G/U rich sequence (4,5). Cleavage of the transcript
occurs between these two elements and is carried out by the
CPSF73 endonuclease, which is part of the Cleavage and
Polyadenylation Speciﬁcity Factor (CPSF) complex (6).
Other protein complexes including Cleavage Stimulation
Factor (CstF), Cleavage Factors I and II (CFIm and
CFIIm) are also required (7). The upstream cleavage
product is polyadenylated to form the mRNA, whereas
the downstream product is rapidly degraded in a process
linked to termination of RNA polymerase II (Pol II) (8,9).
First observed 30 years ago (10), it is now established
that there is reciprocal functional coupling between
splicing and 30 end processing of RNA (11,12). This is
through deﬁnition of the last exon, which requires a
terminal splice acceptor (tSA) site and a pA signal.
Mutation of either sequence disrupts both splicing and
30 end formation as well as the linked process of transcrip-
tional termination (12). In addition, trans-acting factors
play a role by forming bridging contacts across the
terminal exon. Prominent among these are U2AF65,
which binds cleavage factor Im and poly(A) polymerase
(13,14), and SF3b components, which interact with the
CPSF complex (15). A large-scale puriﬁcation of the 30
end processing complex identiﬁed other splicing factors
that may function analogously (16).
30 end formation is also negatively regulated by certain
splicing factors. Early experiments showed that 50 splice
site sequences are involved in silencing some viral pA
signals through the recruitment of U1 snRNA (17–20).
More recently, U1 was found to suppress the processing
of a huge number of pA signals embedded within human
pre-mRNAs (21,22). There must therefore be a
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mechanism of co-ordinating this suppression with activa-
tion by later splicing factors to establish coupling with 30
end formation.
The complex regulation of 30 end formation by splicing
should be considered in the context of transcription, to
which both reactions are coupled in vivo (23). This is
achieved by ternary interactions between processing
factors, the pre-mRNA transcript and the C-terminal
domain of the large subunit of Pol II. Consequently, co-
transcriptional splicing of introns is common (24–27).
However, introns near to the 30 end of a transcript fre-
quently display a lower incidence of co-transcriptional
removal (25,28,29).
We have used several different approaches to determine
how and when splicing is coupled to 30 end formation. We
mutated the tSA site in a chromosomally integrated b-
globin gene. This inhibited splicing and 30 end formation
in a manner involving U1 snRNA and was associated with
the loss of U2AF recruitment to the tSA site. To further
analyse the requirements for tSA site function, we blocked
splicing at subsequent stages using the small molecule
Spliceostatin A (SSA) and by inhibiting U4 snRNA.
These approaches reduced splicing but surprisingly had
little effect on 30 end formation. Thus, a tSA site
establishes coupling between splicing and 30 end forma-
tion, which is sufﬁcient for cleavage and polyadenylation
even when intron removal is inefﬁcient.
MATERIALS AND METHODS
Plasmids
The b-globin plasmid for Figure 5 (b5-7) has been
described previously (30) as has the Tat plasmid (31).
The VA plasmid contains the adenovirus VAI gene and
was a gift from Nick Proudfoot. For the bWT cell line,
b-globin and a portion of 30 ﬂank was ampliﬁed from
b5-10 (30) using primers bE1F and bFR. This was
inserted into the pcDNA5/FRT/TO vector that was ini-
tially linearized by PCR with primers pcF and pcR. This
new vector (bWT) was used as a template for site-directed
mutagenesis with primers tSAmF and tSAmR for the
btSA cell line and with bpAmF and pAmR for the
pAmF line. bWTCoTC was made in the same way as
bWT, but the insert was generated by PCR ampliﬁcation
of the previously described b5-7 (30) plasmid with bE1F
and bFR.
Cell culture
Cells were grown in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% foetal calf serum. SSA was used
at 50 ng/ml unless otherwise stated. Actinomycin D
(ActD) was used at 10 mg/ml. Electroporation was per-
formed on a conﬂuent 10-cm diameter dish of cells using
10–15mM anti-sense morpholino (AMO) in 400 ml of
Dulbecco’s modiﬁed Eagle’s medium using a 4-mm gap
cuvette (960 mF, 280 v in a Biorad gene pulser). RNA
was isolated 3 h after electroporation. For transient trans-
fection, 2.5 mg of reporter and 0.5mg VA were introduced
using Xtreme gene (Roche). For anti-sense oligonucleotide
(ASO) experiments, 500 pmol of oligo was introduced into
a 24-well dish of cells using Lipofectamine RNAiMax
(Life Technologies). For all plasmid and ASO transfec-
tions, RNA was isolated after 24 h. For stable integration,
a 6-cm dish of Flp-IN HEK cells was transfected with 1 mg
of the appropriate b-globin plasmid in addition to 3 mg of
pOG44 using JetPrime (Polyplus) transfection reagent.
Forty-eight h post-transfection, cells were transferred to
a tissue culture ﬂask and grown in the presence of
Hygromycin (100mg/ml) and Blasticidin (10mg/ml) until
resistant cells emerged. Transcription was induced by
overnight growth in media supplemented with 1 mg/ml
tetracycline (tet).
Antibodies
Pol II (N20, Santa Cruz); anti-CstF77 (Sigma, C0249);
anti-U2AF65 (Sigma, U4758).
RNA isolation
Chromatin-associated and nucleoplasmic RNA was
isolated as previously described (32,33). RNA was treated
twice with Turbo DNase (Ambion). Fractionation efﬁ-
ciency was determined by detection of endogenous U1.
Total RNA was isolated using Trizol (Life Technologies).
For real-time PCR analysis, 1mg of RNA was reverse
transcribed using Inprom II (Promega). Parallel reactions
were performed in the absence of reverse transcriptase. In
all, 1/20th of the cDNA mix was used for real-time PCR
using 5–10pmol of forward and reverse primer and
Brilliant III SYBR mix (Agilent Technologies) in a
Qiagen Rotorgene machine. Differences were calculated
using comparative quantitation.
Chromatin and RNA Immunoprecipitation and S1
nuclease analysis
Detailed protocols are provided in the supplementary
material.
Primer sequences
Primer, AMO and ASO sequences are provided in the
supplementary material.
RESULTS
A tSA site is required for maximal 30 end formation in a
chromosomal context
To analyse coupling between splicing and 30 end forma-
tion in a chromosomal context, we constructed two HEK
cell lines containing either a single stably integrated wild-
type (bWT) b-globin gene or one with a mutated tSA site
(btSA) (Figure 1A). Transcription was under the control
of a tet-inducible CMV promoter. To verify the two cell
lines, total RNA was isolated from bWT or btSA cells
after overnight growth in media supplemented or not
with tet. Random hexamer generated cDNA was
analysed by PCR to detect unspliced (Ex2-In2) and
spliced (Ex2-Ex3) b-globin transcripts (Figure 1B).
Unspliced RNA was detected in both the bWT and
btSA lines, and levels were increased following tet induc-
tion. There was a higher level of unspliced intron 2 in
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btSA samples in line with the expected splice inhibitory
effect of the mutation. Correctly spliced b-globin was
detected only in samples from bWT cells, again displaying
a tet-dependent increase. Endogenous b-globin is not ex-
pressed in HEK cells (34).
To test whether the btSA mutation affected 30 end for-
mation in the chromosomal context as it does in plasmids
(12), we performed 30 RACE analysis on total RNA from
tet-induced bWT and btSA cells (Figure 1C). A tagged
oligo-dT was used for reverse transcription, and subse-
quent PCR was done with primers directed to the tag
and to exon 3 to detect all polyadenylated species. A
strong band was detected in the bWT sample, but a
much weaker band was detected in btSA cells indicating
little processing in that case (8-fold less than bWT). We
also analysed random hexamer generated cDNA using
primers spanning the pA site to detect b-globin transcripts
that were not 30 end processed (Figure 1D). The tSA site
mutation resulted in a 3–4-fold accumulation of this
species compared with bWT samples, which is again con-
sistent with reduced 30 end formation. This was also
associated with a mild reduction in the recruitment of
CstF77 pA-processing factor to the btSA gene
(Supplementary Figure S1).
As pre-mRNA processing defects often reduce
transcription (35–37), we tested whether this was the
case on btSA. There was little difference in the abundance
of unspliced intron 1 in bWT and btSA cell lines
(Figure 1E), which we used as a proxy for transcriptional
activity. We also analysed Pol II loading on the bWT-
and btSA-mutated b-globin genes using chromatin
immunoprecipitation (ChIP) (Figure 1F). This was
assessed at three positions across the gene using an
antibody that detects all forms of Pol II (N20). No signiﬁ-
cant differences were observed over any of the regions
between the two cell lines, indicating that similar levels
of Pol II were present. Collectively, these data demon-
strate that the tSA site mutation inhibits splicing and 30
end processing, which is not mediated through obvious
reductions in transcription in this context.
Mutation of a tSA site is also predicted to prevent the
recruitment of relevant 30 splice site-binding factors that
participate in terminal exon deﬁnition. We tested this by
performing RNA immunoprecipitation (RIP) to ana-
lyse binding of the 65 kDa component of U2AF,
U2AF65, to the tSA site of bWT or btSA transcripts.
Immunoprecipitated RNA was reverse transcribed with
random hexamers and then PCR ampliﬁed with primers
across the tSA site. Histone H1E mRNA was used as a
negative control, as U2AF65 is not expected to bind this
transcript. A 4–5-fold greater proportion of bWT tSA site-
containing transcripts were recovered in comparison
(Figure 1G). In contrast, equivalent btSA transcripts
were close to this background level, suggesting that
U2AF is poorly recruited in the absence of a tSA site.
This is in line with previous observations that the splice
site AG dinucleotide is important for its efﬁcient associ-
ation with RNA (38,39). Its absence from btSA transcripts
correlates with their poor processing and with data from
several laboratories showing U2AF65 to promote
cleavage and polyadenylation (13,40,41).
30 end processing of btSA pre-mRNA is activated by
inhibition of U1 snRNA
In addition to blocking the recruitment of factors that
may act positively in 30 end formation, a tSA site
mutation may also leave the pA signal vulnerable to
negative effects. In particular, U1 inhibits cleavage and
polyadenylation at pA sites when bound to nearby 50
splice sites (17,21,22,42), which are all intact in btSA tran-
scripts. To test whether this was the case, we inhibited the
ability of U1 to interact with pre-mRNA using an ASO
that binds to its 50 end (43,44). Treatment with the ASO is
therefore predicted to block the earliest steps in
spliceosome assembly. Transfection of the U1 ASO into
bWT and btSA HEK cells induced premature 30 end for-
mation within the NR3C1 pre-mRNA, which is a known
consequence of U1 inhibition and conﬁrms the effective-
ness of the approach (22) (Figure 2A).
To determine the effect of U1 inhibition on b-globin
splicing, reverse transcription and real-time PCR were
used to quantitate the level of unspliced intron 2 (Ex2-
In2), intron 2 lariat, spliced (Ex2-Ex3) and total (Ex3) b-
globin transcripts (Figure 2B and C). For bWT cells, U1
ASO caused a signiﬁcant increase in unspliced intron 2
and a decrease of lariat intron 2 consistent with splicing
inhibition. Little change in total or spliced bWT RNA was
seen following U1 ASO treatment potentially because
these species are stable or because some splicing still
occurs. For btSA cells, U1 ASO treatment caused an
increase in amounts of unspliced intron 2 and exon 3,
but spliced transcripts remained at low levels as expected.
To test for the effect of depleting U1 binding on 30 end
formation, we quantitatively analysed unspliced pre-
mRNA that was 30 end processed (Figure 2D). To assay
RNAs for which splicing was inhibited, RNA from
control or U1 ASO-treated cells was reverse transcribed
with a tagged oligo-dT probe and then ampliﬁed using the
tag primer and a primer within intron 2. Only authentic 30
end-processed RNA is detected by this approach, as it is
absent when the pA signal is mutated (Supplementary
Figure S2). U1 inhibition caused a 2-fold increase of this
species in bWT cells, suggesting that 30 end formation
occurs when U1 is not recruited to the natural intron.
Interestingly, a similar effect on 30 end processing was
observed in btSA cells. Furthermore, an AMO targeting
U1 gave the same result in btSA plasmid transfected HeLa
cells treated for only 3 hours (Figure 2E). This enhance-
ment of 30 end formation of btSA transcripts strongly
suggests that bound U1 normally plays a role in suppress-
ing cleavage and polyadenylation in this situation. This is
consistent with the conﬁrmed function of U1 bound to 50
splice site sequences, which are all intact in btSA, in in-
hibiting cleavage and polyadenylation (21,22,42).
30 end formation occurs in the presence of SSA in a tSA
site-dependent manner
The data so far show that 30 end formation requires a tSA
site and that, in part, this is to alleviate the negative effects
of U1. We were next interested in testing whether a block
to splicing that occurs after tSA site recognition would
impair 30 end formation. SSA was used, as it blocks
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splicing after U1 and U2 have bound the RNA but before
catalysis (45–47). Unlike the tSA site mutation, SSA does
not affect the recruitment of U2AF65 (47,48), suggesting
that recognition of the 30 splice site still occurs. As SSA
blocks splicing before catalysis, this experiment also tests
whether intron excision plays a role in coupling splicing
and 30 end formation.
We ﬁrst determined the effect of SSA on b-globin
splicing using both the bWT and btSA HEK cell lines.
Total RNA was isolated from cells treated with SSA or
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Figure 1. (A) Diagram of WT and tSA mutated b-globin genes integrated into the HEK cell genome. The tet-inducible CMV promoter (arrow),
exons (numbered boxes) and poly(A) site (pA) are indicated. WT (AG) and mutant (TT) tSA sites are shown. (B) Conﬁrmation of tet-inducible
transcription of b-globin in bWT and btSA HEK cells. Agarose gels show, from the top, unspliced intron 2 (Ex2-In2) RNA, a control where reverse
transcriptase was excluded, spliced (Ex2-Ex3) and a U1 snRNA loading control. (C) 30 RACE analysis of cleaved and polyadenylated bWT and btSA
RNA. Diagram shows tag primer used for cDNA synthesis and partner primer in exon 3 (black arrow). Agarose gel shows 30 end-processed b-globin
RNA (bpA) and the U1 loading control. Real-time PCR quantitation is shown underneath where btSA values are given as a percentage of bWT.
(D) Real-time PCR of non-pA cleaved bWT and btSA transcripts. Diagram shows PCR primers that span the pA site. Graph shows quantitation
where the levels in btSA cells are plotted as a fold change relative to those in bWT cells (set to 1 following normalisation to U1 levels). (E) Real-time
PCR of exon1–intron 1 RNA in bWT and btSA samples. Diagram shows PCR primers that span the 50 splice site of intron 1. Graph shows
quantitation where the levels in btSA cells are plotted as a fold change relative to those in bWT cells (set to 1 following normalization to U1 levels).
(F) ChIP analysis of Pol II loading on bWT and btSA genes. Diagram shows b-globin gene and positions of PCR amplicons. Graph shows the
percentage of DNA immunoprecipitated. (G) RIP analysis of U2AF65 binding to the tSA site of b-globin pre-mRNA in bWT or btSA lines.
Quantitation is expressed as percentage input. Values obtained from Histone H1E (used as a negative control) are also shown. Error bars show
standard deviation (SD) from at least three biological repeats. Astrisk denotes P< 0.05 for btSA versus bWT.
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its methanol (MeOH) solvent. Treatment was limited to
3 h to limit potential off-target effects of splicing inhib-
ition. Real-time PCR was then used to quantitate the
level of unspliced intron 2 (Ex2-In2), intron 2 lariat,
spliced (Ex2-Ex3) and total (Ex3) b-globin transcripts
(Figure 3A and B). In bWT cells, SSA increased the
level of intron 2 and reduced the amount of lariat inter-
mediate, demonstrating a strong inhibition of splicing
before catalysis. By this measure, inhibition was more ef-
ﬁcient than with the U1 ASO. Intron 2 levels were also
increased in btSA cells treated with SSA owing to inhib-
ition of a less frequent cryptic splicing event
(Supplementary Figure S3). Little SSA-dependent
change in total or spliced bWT RNA was seen potentially
because stable processed transcripts are present from
before this short splicing block. As expected, total and
correctly spliced btSA transcripts were present at low
levels or absent, respectively.
To analyse 30 end formation, we detected b-globin tran-
scripts that were not cleaved at the pA site (Figure 3C).
We also analysed 30 ﬂanking RNA, as transcriptional
read-through is a feature of improper pA site function.
SSA treatment resulted in a modest increase in uncleaved
bWT pA sites (1.6-fold) and 30 ﬂanking (2-fold)
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Figure 2. (A) Diagram shows 30 RACE detection of premature 30 end formation within intron 2 of the NR3C1 transcript. Top panel shows this
processed product in bWT or btSA cells transfected with control or U1 ASO. Lower panel shows intronless TAF7 loading control. (B) Diagram
depicting primers used for quantitative RT-PCR analysis of b-globin transcripts. The b-globin gene is shown along with primers (black arrows) to
detect unspliced intron 2 (Ex2-In2), spliced (Ex2-Ex3), total (Ex3) as well as the excised lariat intron 2. (C) Real-time PCR quantitation of Ex2-In2,
Lariat, Ex2-Ex3 and Ex3 RNA in total RNA from bWT and btSA HEK cells transfected with control or U1 ASO. Values are expressed as a fold-
change relative to control ASO-treated bWT (given a value of 1 after normalizing to HistH1E). (D) Quantitative 30 RACE analysis of b-globin RNA
from samples isolated from control or U1 ASO-treated bWT and btSA HEK cells. Diagram shows primers used to detect the unspliced 30 end
processed product. For both the bWT and btSA experiments, the value obtained in U1 ASO samples is expressed as a fold increase over that
obtained in control samples (given a value of 1 in each case after normalizing to HistH1E). (E) Quantitative 30 RACE analysis of unspliced 30 end
processed RNA from HeLa cells transiently transfected with a btSA plasmid and electroporated with control or U1 AMO. Values are expressed as a
fold increase as compared control AMO-treated samples (given a value of 1 after normalizing to HistH1E). Error bars show SD from at least three
biological repeats. Asterisk denotes where P< 0.05 for U1 AMO/ASO-dependent changes.
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transcripts indicating a potential effect on 30 end forma-
tion. However, an SSA-dependent effect of similar magni-
tude was observed in btSA samples. Given that
pA cleavage is substantially less efﬁcient for btSA
(Figure 1C), it is unlikely that a 30 end processing defect
is responsible for this.
To further determine the effect of SSA on b-globin 30
end formation, we used another cell line (bWTCoTC).
This is the same as bWT but has a sequence (the CoTC
element) in the 30 ﬂank, which promotes transcriptional
termination in both plasmid and chromosomal environ-
ments (30,34). An efﬁcient termination process would
reduce the synthesis of any read-through RNA, which
might be somehow stabilized following SSA treatment.
More importantly, however, if the effect of SSA is on
processing at the b-globin pA site, this would still be
seen, as this sequence is identical to bWT. Figure 3D
shows that SSA inhibits terminal intron splicing on
bWTCoTC RNA as for bWT, as intron 2 and lariat
signals are, respectively, increased and decreased by
similar amounts. However, in bWTCoTC cells, SSA did
not affect the level of non-pA cleaved or ﬂank RNA. This
result does not support substantial inhibition of b-globin
30 end formation by SSA. In line with this conclusion, an
A
D
C
E
R
el
at
ive
 
R
N
A 
le
ve
l
SS
A/
M
e
O
H
B
R
el
at
ive
 
R
N
A 
le
ve
l
SS
A/
M
e
O
H
2 3 AAA
Re
la
tiv
e
 
RN
A 
le
ve
lβWT MeOH
βWT SSA
βtSA MeOH
βtSA SSA
R
el
a
tiv
e
 R
N
A 
le
ve
l
1 2 3
pA
CoTC
β-globin
pA
1 2
2
3
3
Ex2-In2            Ex3      UCPA          Flank 
Ex2-Ex3
~1.9 kb                            0.6kb
TTT
βWT MeOH
βWT SSA
βtSA MeOH
βtSA SSA
βWTCoTC
TET
0
1
2
3
4
5
6
Ex2-In2 Lariat Ex2-Ex3 Ex3
0
2
4
6
8
10
UCPA Flank
0
0.5
1
1.5
2
2.5
Ex2-In2 Lariat Ex3 UCPA Flank
0
0.5
1
1.5
2
2.5
βWT βWTCoTC βtSA
*
*
*
*
*
*
*
*
*
*
*
Figure 3. (A) Diagram depicting primers used for quantitative RT-PCR analysis of b-globin transcripts. Labels are as with Figure 2B with the
addition of, non-pA cleaved (UCPA) and ﬂank primers. (B) Real-time PCR quantitation of Ex2-In2, Lariat, Ex2-Ex3 and Ex3 RNA in total RNA
from bWT and btSA HEK cells treated with MeOH or SSA. Following normalization to U1 levels, values are expressed as a fold change relative to
those obtained in WT MeOH treated samples (given a value of 1). (C) Real-time PCR quantitation of non-pA-cleaved and ﬂank RNA in total RNA
from bWT and btSA HEK cells treated with MeOH or SSA. Following normalization to U1 levels, values are expressed as a fold change relative to
those obtained in bWT MeOH-treated samples (given a value of 1). (D) Real-time PCR quantitation of Ex2-In2, lariat, Ex3, UCPA and ﬂank RNA
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of 1) after adjustment to U1 RNA levels. (E) Quantitative 30 RACE analysis of b-globin RNA from samples isolated from MeOH or SSA treated
bWT, bWTCoTC and btSA HEK cells. Diagram shows tagged reverse transcription and intron 2 primers. For each cell line. SSA samples are
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least three biological repeats. Asterisk denotes P< 0.05 for SSA-dependent changes.
7106 Nucleic Acids Research, 2013, Vol. 41, No. 14
independent study showed a modest reduction in b-globin
read-though, following 24 h of SSA treatment, using a
similar stable integrate (48).
If 30 end formation does continue in the presence of
SSA, cleaved and polyadenylated transcripts that are
also unspliced will accumulate. To test this and any
function for a tSA site, we used our 30 RACE approach
to detect these transcripts (Figure 3E). SSA induced a
2-fold increase in unspliced 30 end processed RNA re-
covered from bWT and bWTCoTC cells. Importantly,
however, there was a lack of SSA effect on 30 end forma-
tion of btSA transcripts, which is in contrast to what is
seen by U1 inhibition. Thus, a tSA site is required for 30
end formation when splicing is impaired by SSA, but not
when prior steps in spliceosome assembly are blocked by
inhibiting U1. This is consistent with the idea that recruit-
ment of U1 inhibits cleavage and polyadenylation until a
functional tSA site is encountered. However, although a
tSA site is required for 30 end formation in the presence of
SSA, subsequent intron removal is less critical, as
unspliced 30 end processed bWT and bWTCoTC RNA
accumulates.
U1 snRNA inhibition and SSA do not affect 30 end
formation of P27 and Myc transcripts
We next wanted to analyse the effects of U1 inhibition and
SSA on transcripts synthesised from genes in their natural
chromosomal context. P27 and Myc transcripts were
chosen, as they have previously been used to study
effects of SSA (48,49). Moreover, they have no obvious
sites for premature cleavage and polyadenylation, which is
a widespread consequence of U1 inhibition (22). We ﬁrst
tested the effects of U1 inhibition by electroporating HeLa
cells with a control AMO or one that binds the pre-
mRNA interacting region of U1 (22). An AMO was
used, as it can be electroporated into HeLa cells
facilitating a more rapid inhibition of splicing than ASO
transfection (we were unable to introduce AMOs into our
HEK cells). Accordingly, total RNA was isolated after 3 h
and reverse transcribed. We then used primer sets to detect
unspliced, spliced and non-pA cleaved P27 or Myc RNA
(Figure 4A). Consistent with splicing inhibition, we
observed a substantial increase in unspliced RNA for
both transcripts, with a more modest decrease in spliced
RNA, likely owing to its stability. There was no change in
the level of non-pA cleaved RNA indicating that 30 end
processing remains functional in the absence of U1 and
early spliceosome assembly. Finally, U2AF65 RIP
analysis revealed that it associates with P27 and Myc tran-
scripts with similar efﬁciency in control and U1 AMO-
treated cells (Figure 4B). Thus, although U1 AMO
inhibits U1 binding and pre-mRNA splicing, the intact
30 splice site can still recruit some U2AF. This might be
due to terminal exon deﬁnition requiring an intact 30 splice
site and pA signal (11,50), which are present in this situ-
ation. In sum, these data show that 30 end processing can
proceed when splicing is impaired by preventing U1 from
interacting with pre-mRNA. This is similar to our
b-globin observations and reports that many pA signals
are activated when U1 is inhibited in this way (21,22).
We next analysed the effects of blocking later steps in
spliceosome assembly using SSA. Total RNA was isolated
from cells treated with MeOH or SSA. Following reverse
transcription, cDNA was analysed with primers to detect
unspliced, non-pA cleaved and spliced RNA from Myc
and P27 genes (Figure 4C). In both cases, SSA treatment
caused a large accumulation of unspliced transcripts when
compared with the MeOH control. SSA also caused a
strong reduction in the level of spliced Myc and P27
RNA consistent with a substantial inhibition of splicing.
Despite this, there was little effect of SSA on the level of
non-pA cleaved RNA arguing that, although splicing was
inhibited, 30 end formation was still occurring.
Consistently, an anchored oligo-dT RT-PCR revealed
little effect of SSA on the total level of 30 end processed
P27 and Myc RNA, despite the spliced versions of each
being depleted (Figure 4D). These effects were also
observed when lower concentrations of SSA were used
and when shorter time points were used (Supplementary
Figure S4). This is again consistent with our b-globin
analyses.
A U4 AMO is a rapid and potent splicing inhibitor
We found it surprising that SSA-induced splicing inhib-
ition did not observably impact on 30 end formation. To
be more conﬁdent about this ﬁnding, we sought an alter-
native means of inhibiting a similar step of splicing and
used an AMO directed to U4 (Figure 5A). The region of
U4 targeted by our AMO is required to form a stem with
U6 that is essential for active splicing (51). Pre-mRNA
injected into Xenopus Oocytes that contain U4 lacking
this region can only associate with U1 and U2 (52).
Consistently, treatment with our U4 AMO causes a sub-
stantial reduction in the level of chromatin-associated U4,
U5 and U6 but has less effect on the recovery of U1 and
U2 (Supplementary Figure S5).
We validated the effectiveness of the U4 AMO in vivo
by electroporating it into HeLa cells that were transiently
transfected with a b-globin expression plasmid
(Figure 5B). Total RNA was isolated after 3 h to avoid
off target effects, and cDNA was generated with random
hexamers. PCR was performed with primers in b-globin
exons 1 and 2 or in exons 2 and 3. In control AMO
samples, these primers detected mostly spliced RNA
with a fainter band corresponding to unspliced transcripts.
In the U4 AMO sample, we observed a reduction in
spliced RNA and a large increase in unspliced precursor.
Splicing is inhibited before catalysis because accumulation
of lariat from intron 2 was strongly reduced by the U4
AMO (Supplementary Figure S6A).
We next tested whether the reduced b-globin splicing
caused corresponding effects on 30 end formation. We per-
formed S1 nuclease analysis on the same RNA samples as
Figure 5B (Figure 5C). Transcripts were probed with end-
labelled DNA speciﬁc to the b-globin 30 end or the trans-
fection control VA RNA. Levels of VA RNA are similar
in both samples indicating equivalent transfection.
Strikingly, there was also little difference in the level of
RNA cleaved at the pA site. Thus, although splicing is
severely compromised by U4 inhibition, 30 end processing
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still occurs. As with SSA, unspliced 30 end processed RNA
was produced following U4 inhibition in a manner
requiring a tSA site (Supplementary Figure S6B and C).
Analysis of prematurely processed NR3C1 revealed that
the ability of U1 to bind pre-mRNA and inhibit prema-
ture 30 end formation is largely unaffected by U4 AMO
treatment (Supplementary Figure S7).
It is well established that there is an intimate relation-
ship between pA signal function and transcriptional ter-
mination. Therefore, as a ﬁnal measure of the effect of
U4 inhibition on 30 end formation, we checked its effect
on transcriptional termination (Figure 5D). RNA was
isolated from transfected control or U4 AMO-treated
cells, and qRT-PCR was performed to detect non-pA
cleaved transcripts and read-through RNA from three dif-
ferent positions 30 of the pA signal. Signals were
normalized following adjustment to co-transfected VA
RNA levels. There was no increase in read-through
RNA at any of the positions tested, suggesting that ter-
mination continues to occur on the b-globin plasmid fol-
lowing U4 AMO treatment. Termination is therefore
independent of intron removal when splicing is blocked
through inhibition of U4.
U4 AMO inhibits P27 and Myc splicing, but not 30 end
formation
We next analysed the effect of U4 inhibition on endogen-
ous P27 and Myc transcripts by performing qRT-PCR to
detect unspliced, spliced and non-pA cleaved sampled in
control or U4 AMO-treated cells (Figure 6A). We
observed a large increase in unspliced RNA levels with a
reduction of spliced RNA on U4 AMO treatment
demonstrating effective splicing inhibition. Consistent
with a lack of effect on 30 end formation, U4 inhibition
did not increase the amount of non-pA cleaved RNA that
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was recovered. As with SSA, this result was maintained at
lower concentrations of AMO, which makes it unlikely
that saturation of a key factor is responsible for the ob-
servation (Supplementary Figure S8). A lack of effect on
processing at the P27 and Myc pA sites was also con-
ﬁrmed using an anchored oligo-dT reverse transcription
and real-time PCR approach (Supplementary Figure S9).
We also performed U2AF65 RIP to assess its binding to
the tSA site of Myc and P27 transcripts in control and U4
AMO samples (Figure 6B). A similar proportion of tSA
containing transcripts were bound by U2AF65 in control
and U4 AMO samples. However, unlike with U1 AMO,
the association of U1 snRNA with pre-mRNA remains ef-
ﬁcient under these conditions (Supplementary Figure S7).
This is consistent with the prediction, from previous data
and from the classical splicing pathway (52), that inhib-
ition of U4 in this way blocks splicing following the re-
cruitment of U1 and U2 to the 50 and 30 splice sites.
U4 AMO does not affect recruitment of Pol II and
CstF77 to the Myc gene
Having analysed the pre-mRNA levels and 30 splice site
occupancy by U2AF65, we next tested the effects of U4
inhibition on Pol II density across the Myc gene. This is
important as changes in the level of various pre-mRNA
species may also result from differences in the abundance
of transcribing Pol II. Indeed, splicing perturbation is
sometimes associated with changes in Pol II loading on
genes (35,36,53). We performed Pol II ChIP (using the
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N20 antibody) in control and U4 AMO-treated cells
using primer pairs along the Myc gene. Primer sets
were also located within the 30 ﬂanking region to
analyse transcriptional termination (Figure 6C).
Comparing control and U4 AMO samples revealed no
difference in Pol II loading over any of the positions
tested including those downstream of the pA site.
This shows that U4 inhibition does not cause changes
in transcription or defects in termination as measured
by ChIP.
We next wanted to test the effects of U4 inhibition on
the recruitment of cleavage and polyadenylation factors to
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the Myc gene. For many such factors, this is readily
observed by ChIP. For instance, members of the CstF
complex are found recruited at and beyond the pA
signal consistent with their biological function in 30 end
formation (54). We therefore assayed the recruitment of
CstF77 in both control and U4 AMO-treated samples
using ChIP (Figure 6D). In control cells, CstF77 signal
was strongest at positions downstream of the pA site,
which is consistent with previous observations (54).
Importantly, a similar proﬁle was observed in U4 AMO-
treated samples indicating that, even when splicing is
impaired in this manner, the 30 end processing complex
is present to potentially execute rapid 30 end formation.
U4 AMO causes release of pre-mRNA into the
nucleoplasm and enhances its stability
Mutations that prevent pre-mRNA splicing cause
aberrant transcripts to be retained at their site of synthesis
(35,36,53,55,56). However, it is notable that cis-mutations
block splicing at earlier points to where the U4 AMO is
predicted to act. With this in mind, we assessed the intra-
nuclear distribution of unspliced pre-mRNA following
control or U4 AMO treatment. A well-established tech-
nique was used to isolate chromatin-associated and
nucleoplasmic RNA (33). We then used qRT-PCR to
detect unspliced and non-pA cleaved P27 and Myc tran-
scripts (Figure 7A). U4 AMO treatment caused an
increase in the level of chromatin-associated unspliced
P27 and Myc transcripts consistent with inhibition of
co-transcriptional splicing. Strikingly, U4 AMO treatment
also caused a strong accumulation of unspliced transcripts
in the nucleoplasm, indicating that they are released from
chromatin. In contrast, non-pA cleaved RNA was largely
conﬁned to the chromatin fraction in control and U4
AMO samples consistent with co-transcriptional 30 end
formation in both conditions. This experiment suggests
that, in contrast to RNA containing cis-mutations that
inactivate early steps in splicing, the U4 AMO results in
the accumulation of many unspliced transcripts in the nu-
cleoplasm. This is in line with the independent observation
that SSA induces the accumulation of polyadenylated
RNA in nucleoplasmic foci (45).
Aberrant pre-mRNAs are often rapidly degraded as a
consequence of their retention at transcription sites (35).
We therefore wished to test the hypothesis that the 30 end
processing and release of pre-mRNAs into the nucleo-
plasm might stabilize them instead. To do so, we treated
cells with control and U4 AMOs before supplementing
media with actinomycin D (ActD) to inhibit transcription.
The levels of unspliced, spliced, total and non-pA cleaved
transcripts were then measured at various time points
thereafter using RT-PCR on total RNA. Figure 7B
shows the results obtained for the Myc transcripts in
this experiment. In control AMO samples, total and
spliced transcripts are relatively stable up until 40min,
and then they decay. In contrast, both unspliced and
non-pA cleaved transcripts begin to disappear after only
10min, as a consequence of their rapid processing or deg-
radation. In U4 AMO-treated samples, unspliced, spliced
and total RNAs were highly stable. However, the non-pA
cleaved transcripts behaved identically to those in control
samples. These data provide further support for our model
that U4 inhibition does not impair pA site cleavage.
DISCUSSION
Our ﬁndings are consistent with the following model for
the interconnections between splicing and 30 end process-
ing. Assembly of U1 on the 50 splice site of the terminal
intron occurs ﬁrst and serves to inhibit cleavage and
polyadenylation. To overcome this inhibition, a tSA site
is required to promote terminal exon deﬁnition in combin-
ation with a pA signal. Our data indicate that these early
interactions are vital to couple splicing and 30 end forma-
tion, as a tSA site mutation inhibits both processes.
Although splicing catalysis and intron excision occur
shortly after terminal exon deﬁnition is established
under normal circumstances, our results strongly suggest
that splicing catalysis is dispensable for coupled 30 end
formation. This is shown by the apparently efﬁcient 30
end formation that takes place in the presence of SSA or
U4 AMO, both of which block splicing before any cata-
lytic steps.
Our data indicate that 30 end formation is linked to
splicing once U1 is recruited to the transcript because,
once this occurs, cleavage and polyadenylation is inhibited
unless a functional 30 splice site is encountered. Such a
mechanism is consistent with observations of widespread
30 end formation within introns on inhibition of U1
(17,21,22,57). This function of U1 must somehow be
negated at gene ends. Although removal of the intron is
one way that this could happen, our data suggest that 30
end formation can still occur when splicing catalysis is
blocked by SSA or U4 AMO. Under these conditions,
U1 is still able to inhibit pA site processing, suggesting
that it remains bound to pre-mRNA [(22) and
Supplementary Figure S7]. Therefore, the tSA site must
play a role in buffering its negative effects or promoting
cleavage and polyadenylation. This would presumably
involve the recruitment of factors with this function.
U2AF65 is involved in 30 splice site recognition,
terminal exon deﬁnition and has been shown to stimulate
cleavage and polyadenylation. Interestingly, U2AF65 can
promote b-globin 30 end processing when tethered artiﬁ-
cially to the transcript, suggesting that this function does
not require removal of an intron (40). Our ﬁnding that
reduced 30 end formation on tSA mutation is also
associated with a lack of U2AF65 recruitment is correla-
tive with a potential positive function in 30 end formation.
Other factors involved at the 30 splice site may also play a
role here. In particular, a previous study identiﬁed SF3b
components as being important for coupling splicing to 30
end formation in vitro (15). SF3b is also needed for
branch-point recognition by U2, disruption of which
shows a mild 30 end processing defect for some transcripts
(Supplementary Figure S10). More generally, most
splicing factors described as having potential function in
cleavage and polyadenylation are associated with either
U1 or U2 recruitment (15,40,58). This is consistent with
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our model that early events in splicing are important for
coupling.
Global analyses of nascent transcripts show co-
transcriptional removal of a large number of introns
(24,26). However, co-transcriptional splicing is reported
as being less efﬁcient for introns located nearer to the
end of pre-mRNAs (25,28). In those instances, 30 end for-
mation might occur more rapidly than splicing. Indeed,
available analyses indicate that some pA sites are pro-
cessed in a matter of seconds with splicing occurring in
minutes (59,60). Similarly, our actinomycin time course
indicates that unspliced Myc transcripts are processed
more slowly than non-pA cleaved RNA (Figure 7B).
Our data indicate that splicing and 30 end formation can
be coupled in these situations owing to recruitment of U1
to the 50 splice site and U2AF65 (and presumably U2) to
the 30 splice site. This is likely to be a rapid process, as
both factors are present on transcribing Pol II (41,61,62).
It is well documented that many splice defective tran-
scripts in lower and higher eukaryotes are rapidly
degraded (36,53,63). Although this is also true of some
transcripts following SSA treatment, other pre-mRNAs
accumulate and are stabilized (35). We observe a similar
accumulation and stabilization of P27 and Myc transcripts
following U4 AMO treatment. This correlates with their
release into the nucleoplasm, which we propose is
facilitated by the continued cleavage and polyadenylation
that occurs under these splice inhibitory conditions.
Consistently, immunoﬂuorescence experiments demons-
trated that SSA or U4 treatment causes a large accumu-
lation of polyadenylated RNA in nucleoplasmic foci that
co-localize with the splicing speckle marker, SC35 (45) and
our unpublished results. Previous work showed that
unspliced P27 pre-mRNA can be translated following
SSA treatment (45), which may implicate the nonsense-
mediated decay pathway in the turnover of these and
similar transcripts. However, it is not known how
unspliced pre-mRNA that accumulates in intra-nuclear
speckles is eventually exported to the cytoplasm.
We have shown that the tight co-transcriptional
coupling between splicing and 30 end formation is estab-
lished early during terminal exon deﬁnition following U1
recruitment to the 50 splice site and recognition of the tSA
site. These early events seem sufﬁcient to permit 30 end
formation, which continues following blocks to later
steps in the splicing process.
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